Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing-Reference-Cited by-同舟云学术

Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing

Published:2019-08 Issue:8 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Tam Kingsley King-Gee¹,Leung Kenneth Siu-Sing¹,Siu Gilman Kit-Hang²,Chang Kwok-Chiu³^ORCID,Wong Samson Sai-Yin¹,Ho Pak-Leung¹^ORCID,Leung Eunice Ka-Chun¹,Yam Wing-Cheong¹

Affiliation:

1. Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China

2. Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China

3. Tuberculosis and Chest Service, Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region, China

Abstract

An in-house-developed pncA sequencing assay for analysis of pyrazinamide (PZA) resistance was evaluated using 162 archived Mycobacterium tuberculosis complex (MTBC) isolates with phenotypic PZA susceptibility profiles that were well defined by analysis of Bactec MGIT 960 PZA kit and PZase activity data. Preliminary results showed 100% concordance between pncA sequencing and phenotypic PZA drug susceptibility test (DST) results among archived isolates.

Funder

The Hong Kong Tuberculosis, Chest and Heart Diseases Association Scientific Committee on Lung Health

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00145-19

Reference36 articles.

1. WHO. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.

2. Mechanisms of Pyrazinamide Action and Resistance

3. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update

4. The curious characteristics of pyrazinamide: a review;Zhang Y;Int J Tuber Lung Dis,2003

5. WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic mechanisms of co-emergence of INH-resistant Mycobacterium tuberculosis strains during the standard course of antituberculosis therapy;Microbiology Spectrum;2024-04-02

2. Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients;Microbiology Spectrum;2023-06-15

3. Global status of phenotypic pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates: an updated systematic review and meta-analysis;Journal of Chemotherapy;2023-05-21

4. Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics;Drug Resistance Updates;2023-05

5. Surveillance of multidrug-resistant tuberculosis in Taiwan, 2008–2019;Journal of Microbiology, Immunology and Infection;2023-02